Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Marcellin, P; Lau, GKK; Bonino, F; Farci, P; Hadziyannis, S; Jin, R; Lu, ZM; Piratvisuth, T; Germanidis, G; Yurdaydin, C; Diago, M; Gurel, S; Lai, MY; Button, P; Pluck, N

doi:10.1056/nejmoa040431

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Marcellin P., Lau G., Bonino F., Farci P., Hadziyannis S., Jin R., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.351, sa.12, ss.1206-1217, 2004 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 351 Sayı: 12
Basım Tarihi: 2004
Doi Numarası: 10.1056/nejmoa040431
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1206-1217
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Hayır

Özet

Background: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.